Results

1–10 of 267 results for AMD

Treatment of Geographic Atrophy Secondary to AMD With Pegcetacoplan: Two-Year Outcomes From the Randomized Phase 3 DERBY and OAKS Trials
Charles C Wykoff, MD, PhD, FASRS
Updates from the Field
2022
GATHER2 Phase 3 Efficacy Results and GATHER2 Phase 3 Safety Results
Jeffrey S. Heier, MD
Arshad M. Khanani, MD, MA, FASRS
Updates from the Field
2022
Short-term Effects of COVID-19-Related Deferral of Intravitreal Injection Visits
William E. Smiddy, MD
Annual Meeting Talks
2021
Maximum Consecutive Fluid Free Months and Its Association With Visual and Anatomical Outcomes in nAMD: A Post-Hoc Analysis From HAWK and HARRIER
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2021
Suprachoroidal Delivery of RGX-314 for Neovascular AMD: Initial Results From the Phase II AAVIATE Study
Mark R. Barakat, MD
Annual Meeting Talks
2021
Geographic Access Disparities of Clinical Trials in Neovascular Age-Related Macular Degeneration in the United States
Rebecca Soares, MD
Annual Meeting Talks
2021
Faricimab in Neovascular Age-Related Macular Degeneration: Week 48 Efficacy, Safety, and Durability Results From the Phase 3 TENAYA and LUCERNE Trials
Karl G. Csaky, MD, PhD
Annual Meeting Talks
2021
Analysis of Retinal Fluid and Vision Outcomes in the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS) in Patients With nAMD
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2021
Intravitreal Gene Therapy for Neovascular AMD with ADVM-022: Results of the Phase 1 OPTIC Trial
Dante Joseph Pieramici, MD
Annual Meeting Talks
2021
Key Pearls of Conjunctival and Tenon’s Capsule Handling During the Implant Insertion Procedure for the Port Delivery System With Ranibizumab (PDS)
Veeral S. Sheth, MD, MBA, FASRS, FACS
Annual Meeting Talks
2021